

| Market Applicability |    |    |    |    |    |    |    |
|----------------------|----|----|----|----|----|----|----|
| Market               | DC | GA | KY | MD | NJ | NY | WA |
| Applicable           | X  | X  | X  | X  | X  | X  | NA |

## Nasal Triptan Agents Step Therapy

| Override(s)                           | Approval Duration |
|---------------------------------------|-------------------|
| Prior Authorization<br>Quantity Limit | 1 year            |

| Medications                              | Comment       | Quantity Limit                   |
|--|---------------|----------------------------------|
| Sumatriptan Nasal Spray (generic)        | Preferred     | May be subject to quantity limit |
| Brand Imitrex (sumatriptan) nasal spray  | Non-Preferred |                                  |
| Tosymra (sumatriptan) nasal spray        |               |                                  |
| Onzetra Xsail (sumatriptan) nasal powder |               |                                  |
| Zomig (zolmitriptan) nasal spray         |               |                                  |

### APPROVAL CRITERIA

Requests for nasal triptan agents may be approved if the following criteria are met:

- I. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of and inadequate response or intolerance to two **oral** preferred triptan agents: [naratriptan (generic Amerge), sumatriptan (generic Imitrex)];

#### **OR**

- II. Oral triptan agents are not acceptable due to concomitant clinical conditions, such as but not limited to the following:
  - A. Individual is unable to take oral medications due to one of the following:
    1. Individual experiences nausea and vomiting due to migraines; **OR**
    2. Individual requires a more rapid onset of action due to short aura time period; **OR**
    3. Individual cannot swallow tablets and there are no preferred ODT (oral disintegrating tablet) formulations;

#### **AND**

- III. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of and inadequate response or intolerance to Sumatriptan (generic Imitrex) **nasal spray**;

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

| Market Applicability |    |    |    |    |    |    |    |
|----------------------|----|----|----|----|----|----|----|
| Market               | DC | GA | KY | MD | NJ | NY | WA |
| Applicable           | X  | X  | X  | X  | X  | X  | NA |

**OR**

- IV. If request is for Zomig (zolmitriptan) nasal spray, may be approved for individuals between the ages of 12 and 17.

| State Specific Mandates |                |   |
|-------------------------|----------------|---|
| State Name              | Date effective | Mandate details (including specific bill if applicable) |
| N/A                     | N/A            | N/A   |

**Key References:**

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 14, 2018.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
5. Beithon J, Gallenberg M, Johnson K, et al. Diagnosis and Treatment of Headache. Institute for Clinical Systems Improvement. Available from: [https://www.icsi.org/guidelines\\_more/catalog\\_guidelines\\_and\\_more/catalog\\_guidelines/catalog\\_neurological\\_guidelines/headache/](https://www.icsi.org/guidelines_more/catalog_guidelines_and_more/catalog_guidelines/catalog_neurological_guidelines/headache/). Updated January 2013.
6. [The American Headache Society position statement on integrating new migraine treatments into clinical practice. \*Headache\*. 2019; 59:1-18. Available from: <https://onlinelibrary.wiley.com/doi/epdf/10.1111/head.13456>. Accessed April 5, 2019.](#)
7. [Tfelt-Hansen PC. Triptans and ergot alkaloids in the acute treatment of migraine: similarities and differences. \*Expert Rev Neurother\*. 2013; 13\(9\): 961-963. Available from <https://www.tandfonline.com/doi/pdf/10.1586/14737175.2013.832851>. Accessed April 5, 2019.](#)

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.